Wilmington Savings Fund Society FSB Invests $166,000 in VanEck Biotech ETF (NASDAQ:BBH)

Wilmington Savings Fund Society FSB bought a new stake in shares of VanEck Biotech ETF (NASDAQ:BBH) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 938 shares of the company’s stock, valued at approximately $166,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Truvestments Capital LLC bought a new stake in VanEck Biotech ETF during the 3rd quarter valued at approximately $44,000. FSA Wealth Management LLC bought a new position in shares of VanEck Biotech ETF in the 3rd quarter worth approximately $54,000. Coastline Trust Co purchased a new position in shares of VanEck Biotech ETF in the 3rd quarter valued at approximately $59,000. Hyman Charles D bought a new stake in shares of VanEck Biotech ETF during the second quarter valued at approximately $202,000. Finally, Tyler Stone Wealth Management grew its stake in VanEck Biotech ETF by 79.5% in the third quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock worth $261,000 after purchasing an additional 652 shares during the period. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Trading Down 3.5 %

BBH opened at $158.37 on Thursday. The stock has a fifty day simple moving average of $168.90 and a two-hundred day simple moving average of $172.96. VanEck Biotech ETF has a 12-month low of $151.35 and a 12-month high of $183.64.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.